BCD-237 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

4,946 results for “BCD-237”

Trials

View all 3536 →

A Phase III Confirmatory Study of K-237

1,030 participants · First posted Sep 27, 2021

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

45 participants · First posted Sep 19, 2005

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

45 participants · First posted Sep 19, 2005

Drugs

View all 890 →

BCD-236

BCD-231

BCD-235

Organizations

View all 71 →

Afferent Pharmaceuticals, Inc.

United States

KUWAIT UNIVERSITY

Kuwait

New York Eye & Ear Infirmary

United States

News

View all 449 →

Russia's Biocad Initiates Phase III Trial of Kadcyla Biosimilar BCD-237 for HER2-Positive Breast Cancer

Gene Therapy NGGT001 Shows Promising Safety Profile in Bietti's Crystalline Dystrophy Trial

Shanghai Vitalgen Advances VGR-R01 Gene Therapy to Phase 3 Trial for Bietti Crystalline Dystrophy

Page 1 of 495